cocaine addiction, cocaine verslaving, ADHD, methylphenidate, methylfenidaat
Conditions
Interventions
1. MPH study medication (oral
Concerta 54 mg)
2. 2 SPECT scans using the selective radioligand [123I]FP-CIT
3. MRI scan for coregistration
4. Neuropsychological assessments, Questionaires
5. Blood and urine analyses.
Sponsors
Crunelle CL, Booij J, Van den Brink W
Eligibility
Inclusion criteria
Inclusion criteria: 1. Male, age 18-60 years; 2. Current DSM-IV diagnosis of adult ADHD for all participants; 3. For the ADHD+SUD group: Current DSM-IV diagnosis of cocaine dependence, but abstinent from cocaine use for at least 1 week; 4. Able to provide written informed consent and to comply with all study procedures; 5. Negative urine analyses for MPH, amphetamines and cocaine.
Exclusion criteria
Exclusion criteria: 1. Currently dependent on any substance other than cocaine or nicotine; 2. Severe neurological or psychiatric disorders or diseases (e.g., psychosis, bipolar depression, Parkinson¡¯s disease, or dementia) that require psychotropic medications; 3. Serious medical illnesses that would make participation hazardous, such as cardiovascular disease or ECG abnormalities; 4. Known hypersensitivity or allergy to MPH; 5. Under therapy with drug known to influence binding to DATs, including antipsychotics, MPH, bupropion, and dexamphetamine within 30 days prior to randomization; 6. Received a drug with known potential for toxicity to a major organ system within the month prior to entering treatment; 7. Clinically significant abnormal laboratory values (¡Ý3x normal) as measured by the Arkin Mental Health and Addiction treatment center; 8. Any disease of the gastrointestinal system, liver, or kidneys which could result in altered metabolism or excretion of the study medication; 9. Hypersensitivity to iodine; 10. Any contraindications to perform MR imaging (e.g., pacemaker, or any piece of metal in the body).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the effects of a standard dose of methylphenidate (MPH) on Dopamine Transporter (DAT) occupancy in ADHD patients with and without cocaine dependence, in terms of: 1. Striatal occupancy of the DAT; 2. Symptoms of ADHD; 3. Neurocognitive functions associated with ADHD; 4. Drug use/craving (in the ADHD+SUD group); 5. Relations between DAT occupancy, ADHD symptoms, cognitive functions, and drug use/craving. | — |
Contacts
Public ContactCleo L. Crunelle
Academic Medical Center, University of Amsterdam Amsterdam Institute for Addiction Research Department of Psychiatry, PB0-436 P.O. Box 75867
Outcome results
None listed